News | January 26, 2022
JBCPL to acquire brands from Sanzyme for Rs 628 cr
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
The company sees the business reaching $100mn
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)